Cellular Biomedicine Group Analysis
Cellular Biomedicine Group is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Cellular Biomedicine delisted stock analysis is to determine its intrinsic value, which is an estimate of what Cellular Biomedicine Group is worth, separate from its market price. There are two main types of Cellular Biomedicine's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Cellular Biomedicine's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Cellular Biomedicine's stock to identify patterns and trends that may indicate its future price movements.
The Cellular Biomedicine stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cellular Biomedicine is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Cellular Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cellular Biomedicine's ongoing operational relationships across important fundamental and technical indicators.
Cellular |
Cellular Stock Analysis Notes
About 45.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.83. Cellular Biomedicine had not issued any dividends in recent years. The entity had 1:100 split on the 31st of January 2013. Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. As of February 19, 2021, Cellular Biomedicine Group, Inc. was taken private. Cellular Biomedicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 217 people. For more info on Cellular Biomedicine Group please contact Wei Cao at 301 825-5320 or go to www.cellbiomedgroup.com.Cellular Biomedicine Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cellular Biomedicine's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cellular Biomedicine Group or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Cellular Biomedicine is not yet fully synchronised with the market data | |
| Cellular Biomedicine has some characteristics of a very speculative penny stock | |
| Cellular Biomedicine has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 66.39 M in liabilities with Debt to Equity (D/E) ratio of 3.83, implying the company greatly relies on financing operations through barrowing. Cellular Biomedicine has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cellular Biomedicine until it has trouble settling it off, either with new capital or with free cash flow. So, Cellular Biomedicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cellular Biomedicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cellular to invest in growth at high rates of return. When we think about Cellular Biomedicine's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 322.95 K. Net Loss for the year was (54.8 M) with profit before overhead, payroll, taxes, and interest of 277.54 K. | |
| Cellular Biomedicine Group currently holds about 26.03 M in cash with (44.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.34. | |
| Roughly 45.0% of Cellular Biomedicine shares are held by company insiders |
Cellular Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 384.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellular Biomedicine's market, we take the total number of its shares issued and multiply it by Cellular Biomedicine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Cellular Biomedicine to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Cellular Stock
If you are still planning to invest in Cellular Biomedicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cellular Biomedicine's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |